Literature DB >> 30652089

Occult HBV infection status and its impact on surgical outcomes in patients with curative resection for HCV-associated hepatocellular carcinoma.

Koutaro Yamaji1,2, Keita Kai3, Sho Komukai4, Hiroki Koga1, Takao Ide1, Atsushi Kawaguchi5, Hirokazu Noshiro1, Shinichi Aishima2,3.   

Abstract

BACKGROUND: We sought to clarify the prevalence of occult hepatitis B virus (HBV) infection (OBI) and to determine whether OBI affects the surgical outcomes in curatively resected Japanese patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC).
METHODS: A total of 257 patients with HCV-related HCC who underwent curative surgical resection were enrolled. All enrolled patients were serologically negative for HBV surface antigen and positive for HCV antibody. DNA was extracted from formalin-fixed paraffin-embedded liver tissue. OBI was determined by the HBV-DNA amplification of at least two different sets of primers by TaqMan real-time polymerase chain reaction. Surgical outcomes were evaluated according to overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS).
RESULTS: OBI was identified in 15 of the 257 (5.8%) cases. In the multivariate analyses, the factors significantly correlated with OS were BMI >25 (P=0.0416), portal vein invasion (P=0.0065), and multiple tumors (P=0.0064). The only factor significantly correlated with DSS was T-stage (P=0.0275). The factors significantly correlated with DFS were liver fibrosis (P=0.0017) and T-stage (P=0.0001). The status of OBI did not show any significant correlation with OS, DSS or DFS, but a weak association with DSS (P=0.0603) was observed.
CONCLUSIONS: The prevalence of OBI was 5.8% in 257 cases of HCV-related HCC. Although a weak association between DSS and OBI was observed, and statistical analyses were limited by small number of OBI cases, no significant correlation between OBI and surgical outcomes was detected.

Entities:  

Keywords:  Occult hepatitis B virus infection (OBI); hepatitis C virus (HCV); hepatocellular carcinoma (HCC); prognosis; surgery

Year:  2018        PMID: 30652089      PMCID: PMC6295390          DOI: 10.21037/hbsn.2018.10.01

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  49 in total

1.  The impact of previous HBV infection on the course of chronic hepatitis C.

Authors:  N De Maria; A Colantoni; L Friedlander; G Leandro; R Idilman; J Harig; D H Van Thiel
Journal:  Am J Gastroenterol       Date:  2000-12       Impact factor: 10.864

2.  Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis.

Authors:  E Sagnelli; N Coppola; C Scolastico; P Filippini; T Santantonio; T Stroffolini; F Piccinino
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

3.  Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.

Authors:  I Cacciola; T Pollicino; G Squadrito; G Cerenzia; M E Orlando; G Raimondo
Journal:  N Engl J Med       Date:  1999-07-01       Impact factor: 91.245

4.  The influence of occult infection with hepatitis B virus on liver histology and response to interferon treatment in chronic hepatitis C patients.

Authors:  Claudia da Silva; Neiva Sellan Lopes Gonçales; Josiane Silveira Felix Pereira; Cecília Amélia Fazio Escanhoela; Maria Helena Postal Pavan; Fernando Lopes Gonçales
Journal:  Braz J Infect Dis       Date:  2005-05-09       Impact factor: 1.949

5.  Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance.

Authors:  R Fukuda; N Ishimura; M Niigaki; S Hamamoto; S Satoh; S Tanaka; Y Kushiyama; Y Uchida; S Ihihara; S Akagi; M Watanabe; Y Kinoshita
Journal:  J Med Virol       Date:  1999-07       Impact factor: 2.327

6.  Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C.

Authors:  Izumi Hasegawa; Etsuro Orito; Yasuhito Tanaka; Noboru Hirashima; Kenji Sakakibara; Mayumi Sakurai; Seiji Suzuki; Fuminaka Sugauchi; Tomoyoshi Ohno; Ryuzo Ueda; Masashi Mizokami
Journal:  Liver Int       Date:  2005-04       Impact factor: 5.828

7.  Factors associated with the development of cirrhosis in patients with HCV chronic infection.

Authors:  Mario Dinis-Ribeiro; Fernando Ramalho; Helena Glória; Rui Marinho; Miguel Raimundo; Fátima Serejo; José Velosa; Miguel Carneiro-de-Moura
Journal:  Hepatogastroenterology       Date:  2005 Jan-Feb

8.  Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients.

Authors:  Edoardo Giannini; Paola Ceppa; Federica Botta; Alberto Fasoli; Paola Romagnoli; Filippo Ansaldi; Paolo Durando; Domenico Risso; Pasquale B Lantieri; Gian C Icardi; Roberto Testa
Journal:  Liver Int       Date:  2003-02       Impact factor: 5.828

9.  High prevalence of occult hepatitis B in Baltimore injection drug users.

Authors:  Michael Torbenson; Rajesh Kannangai; Jacquie Astemborski; Steffanie A Strathdee; David Vlahov; David L Thomas
Journal:  Hepatology       Date:  2004-01       Impact factor: 17.425

10.  Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection.

Authors:  Teresa Pollicino; Giovanni Squadrito; Giovanni Cerenzia; Irene Cacciola; Giuseppina Raffa; Antonio Craxi; Fabio Farinati; Gabriele Missale; Antonina Smedile; Claudio Tiribelli; Erica Villa; Giovanni Raimondo
Journal:  Gastroenterology       Date:  2004-01       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.